Rethinking the intention-to-treat principle: one size does not fit all
- 1 September 2020
- journal article
- editorial
- Published by Elsevier BV in Journal of Clinical Epidemiology
- Vol. 125, 198-200
- https://doi.org/10.1016/j.jclinepi.2020.04.023
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 DiabetesDiabetes Care, 2019
- Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trialThe Lancet Diabetes & Endocrinology, 2019
- Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trialThe Lancet Diabetes & Endocrinology, 2019
- Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trialThe Lancet, 2019
- Cautions as Regulators Move to End Exclusive Reliance on Intention to TreatAnnals of Internal Medicine, 2018
- Current Practices in Choosing Estimands and Sensitivity Analyses in Clinical Trials: Results of the ICH E9 SurveyTherapeutic Innovation & Regulatory Science, 2017